代谢物
泌尿系统
戊二酸
化学
内科学
酶
排泄
内分泌学
小干扰RNA
药理学
赖氨酸
排泄系统
医学
生物化学
酶替代疗法
新陈代谢
内生
脑病
治疗效果
核糖核酸
治疗方法
生物
脑损伤
ATP合酶
尿
线粒体
疾病
作者
Yunhan Ma,Maiya Fujiwara,Natasha Murugan,Haoyue Zhang,SABRINA BELOZEROVA,James Beasley,Cheryl K. Peck,Timothy C. Wood,Ashlee R. Stiles,Sarah P. Young,Areeg El‐Gharbawy,Mercedes Barzi,Beatrice Bissig-Choisat,Leila J. Noetzli,Karl‐Dimiter Bissig
标识
DOI:10.1126/scitranslmed.aej2067
摘要
Glutaric aciduria type I (GA-1) is a severe metabolic disorder caused by a deficiency of glutaryl-CoA dehydrogenase (GCDH), leading to accumulation of organic acids in the brain and resulting in striatal injury and progressive movement disorders. Although early diagnosis and dietary management reduce risk, one-third of patients still develop debilitating neurological complications. We previously demonstrated that liver-specific deletion of aminoadipate semialdehyde synthase (AASS), an upstream enzyme in lysine degradation, is a promising therapeutic strategy. Here, we tested an N -acetylgalactosamine (GalNAc)–conjugated siRNA against Aass . Treatment of neonatal Gcdh −/− mice rescued lethality and improved the brain pathology while reducing toxic metabolites in the brain and other organs. Serum biomarkers, including glutaric acid, 3-hydroxyglutaric acid, and glutarylcarnitine, predicted neurological outcomes, supporting their use for therapeutic monitoring. Although systemic metabolite concentrations declined, their urinary excretion remained elevated, consistent with a renal washout phenomenon and preserved excretory capacity. These findings demonstrate the potential of liver-targeted small interfering RNA (siRNA) therapy as a treatment for GA-1.
科研通智能强力驱动
Strongly Powered by AbleSci AI